Johnson & Johnson reports 73% PSA response rate in Phase 1 study
Johnson & Johnson said that 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in PSA, and 47 percent (7 of 15 patients) achieved reductions of at least 90 percent. The company noted no Grade 3 or higher treatment-related adverse events in this early analysis.
Primary source
Company press release (PR Newswire), November 8, 2026
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Machine-summarized from the source above; not independently reported. How we use automation